Literature DB >> 6225437

Second course gold therapy in the treatment of rheumatoid arthritis.

A E Evers, W R Sundstrom.   

Abstract

Twenty-three rheumatoid arthritis patients who had previously received gold therapy were selected for second course gold. Eleven patients had developed complete remission during the first course of gold therapy. Four of these had a complete response to second course gold. Of the 10 nonresponders and 2 partial responders to first course gold, none responded to second course gold. We conclude that individuals in whom first course gold is unsuccessful respond poorly to repeated gold treatments. In addition, only 36% of the patients who initially had a complete response sustained complete remission with second course gold.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6225437     DOI: 10.1002/art.1780260903

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  5 in total

Review 1.  Combination chemotherapy in rheumatoid arthritis.

Authors:  P M Brooks; A C Schwarzer
Journal:  Ann Rheum Dis       Date:  1991-07       Impact factor: 19.103

2.  Cultured human cells can acquire resistance to the antiproliferative effect of sodium aurothiomalate.

Authors:  A Glennås; H E Rugstad
Journal:  Ann Rheum Dis       Date:  1986-05       Impact factor: 19.103

3.  Disease-modifying drugs for rheumatoid arthritis. Asset or liability?

Authors:  H A Bird
Journal:  Clin Rheumatol       Date:  1987-12       Impact factor: 2.980

4.  Effect of resumption of second line drugs in patients with rheumatoid arthritis that flared up after treatment discontinuation.

Authors:  S ten Wolde; J Hermans; F C Breedveld; B A Dijkmans
Journal:  Ann Rheum Dis       Date:  1997-04       Impact factor: 19.103

5.  Influence of previous gold treatment and other patient variables on outcome of treatment with disease modifying anti-rheumatic drugs (DMARD) in patients with rheumatoid arthritis.

Authors:  M W Bentzon; I Gad; P Halberg; O Halskov; B K Jacobsen; I Lorenzen; N Morling; A Svejgaard
Journal:  Clin Rheumatol       Date:  1986-01       Impact factor: 2.980

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.